Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States.... Show more
Rating: Strong Buy
Symbol: AGN
Exchange: NYSE
$18.77B

Market cap

Allergan Financial Health

Profitability:1.92/10

Allergan has worst Profitability than 91.67% of the companies on the Drug Manufacturers industry

Net Margin: -16.16%

Allergan has worst Net Margin than 91.67% of the companies on the Drug Manufacturers industry


ROE (Return on Equity): -1.06%

Allergan has worst ROE (Return on Equity) than 90% of the companies on the Drug Manufacturers industry


ROA (Return on Assets): -0.66%

Allergan has worst ROA (Return on Assets) than 91.67% of the companies on the Drug Manufacturers industry


Operating Efficiency:0.62/10

Allergan has worst Operating Efficiency than 91.67% of the companies on the Drug Manufacturers industry

Operating Margin: -35.64%

Allergan has worst Operating Margin than 91.67% of the companies on the Drug Manufacturers industry


Liquidity:3.24/10

Allergan has worst Liquidity than 66.67% of the companies on the Drug Manufacturers industry

Quick Ratio: 0.84

Allergan has worst Quick Ratio than 66.67% of the companies on the Drug Manufacturers industry


Operating Cash Flow Ratio: 0.76

Allergan has better Operating Cash Flow Ratio than 83.33% of the companies on the Drug Manufacturers industry


Solvency:4.46/10

Allergan has worst Solvency than 75% of the companies on the Drug Manufacturers industry

Debt to Equity Ratio: 0.34

Allergan has better Debt to Equity Ratio than 91.67% of the companies on the Drug Manufacturers industry


Interest Coverage Ratio: 0.76

Allergan has better Interest Coverage Ratio than 83.33% of the companies on the Drug Manufacturers industry


Allergan revenue quarter by quarter
Allergan operating expenses

👀 Get a summary of every week for free

Top company news, earnings report, analysis and more.

InspectCompany.com

We aim to help investors learn more about the companies in which they invest. We believe investing should be less about trying to find patterns in charts and more about investing in the companies that better represent your vision for the future.

Disclaimer: InspectCompany does not guarantee that any of the information available on our website, APIs or provided by any other means is complete, accurate, current, reliable or appropriate for your needs. Some of our information is provided by third party services and we cannot guarantee that is complete, accurate, current, reliable or appropriate for your needs. The information and recommendations on this site are for educational purposes only and should not be used to replace the advice of financial advisors and other professionals. All our services, information, data and/or recommendations are provided on an "as is" basis and without warranties of any kind, either express or implied. We do not guarantee that our services, information, data and/or recommendations are complete, accurate, current, reliable or appropriate for your needs.  Read more